Nitinotes Partners with Weill Cornell Medicine for Innovative Trial in Obesity Treatment

In a pivotal development for the treatment of obesity, Nitinotes Ltd. has announced the activation of clinical sites at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center as part of their groundbreaking EASE™ Investigational Device Exemption (IDE) trial. This announcement marks a significant milestone in their ongoing efforts to evaluate the EndoZip™ Automated Suturing System for Endoscopic Sleeve Gastroplasty (ESG).

On August 11, 2026, the first patient was treated in this trial by Dr. Reem Z. Sharaiha, a prominent figure in medicine and the Director of Endoscopy at Weill Cornell. This initial procedure not only signifies the commencement of trials at these distinguished institutions but also underscores the growing importance of innovative approaches to tackling obesity, a major public health challenge.

The EASE™ IDE trial is specifically designed to assess the safety and effectiveness of the EndoZip™ system, which enables a minimally invasive endoscopic procedure aimed at reducing body weight. By engaging multiple leading medical centers with expertise in advanced endoscopic techniques, Nitinotes seeks to create a robust clinical evidence base that can pave the way for better treatment options for obesity.

Lloyd Diamond, CEO of Nitinotes, expressed his enthusiasm about the trial, stating, "The activation of Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center represents an important milestone in the EASE™ IDE trial." He emphasized the need for a standardized approach to performing ESG, reflecting a commitment to enhancing patient outcomes through technology.

Dr. Sharaiha reiterated the urgency of this research, highlighting the pressing need for minimally invasive options that improve access to effective care for individuals struggling with obesity. The trials are integral to generating the necessary clinical evidence that could redefine treatment pathways, ultimately benefiting patients nationwide.

The EASE™ trial is meticulously structured as a prospective, multicenter, randomized, and controlled IDE study. It’s essential for meeting the U.S. Food and Drug Administration (FDA) requirements to market the EndoZip™ system in the United States. Currently, while the system holds a CE mark in Europe, its investigational status in the U.S. emphasizes the ongoing research efforts to validate its efficacy and safety.

Nitinotes is at the forefront of medical innovation, focusing on endoluminal suturing technologies dedicated to combating obesity. The company's flagship product, the EndoZip™, signifies a leap forward by supporting a standardized approach to endoscopic procedures, potentially revolutionizing how obesity is treated. With the commencement of the EASE™ trial, Nitinotes is not only advancing its technology but is also contributing to a broader dialogue surrounding obesity treatment in the medical community. This trial could very well lead to critical changes in clinical practice and accessibility of care as obesity continues to affect millions worldwide.

As Nitinotes prepares to expand enrollment across premier medical centers in the U.S., the results from the EASE™ trial could significantly influence future treatment modalities, making this a landmark moment in obesity management.

For more information on Nitinotes and their innovative endeavors in medical technology, visit Nitinotes Surgical.